Floatz logo

Fremanezumab

Sleep Disorder

Beth Israel Deaconess Medical Centermonoclonal_antibodyPhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
89/ 100

Competitive context

14 Active assets in the Sleep Disorder cohort.

Asset / SponsorPhaseRating
Trazodone
Johns Hopkins University
Phase 4BB
Rasagiline
Technische Universität Dresden
Phase 4BB
Armodafinil
Cephalon
Phase 4BB
Melatonin
Duke University
Phase 3BB
Olanzapine
Central Institute of Psychiatry, Ranchi, India
Phase 4BB

View all 34 →

Same molecule, other indications

Fremanezumab is also rated in:

migraine disorderActive
BBB
Indicative · Phase 4
74 / 100
View asset →
acute mountain sicknessActive
BB
Indicative · Phase 4
65 / 100
View asset →
migraine without auraActive
BB
Indicative · Phase 4
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →